High profile marketing events provide multiple opportunities to introduce CytoSorb to cardiac surgeons and perfusionists throughout Europe
MONMOUTH JUNCTION, N.J., Oct. 3, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorporeal cytokine adsorber that targets the reduction of excessive inflammatory mediators in critically-ill and cardiac surgery patients, announced today that the company and its strategic partner, Terumo Cardiovascular Group, have initiated international marketing of CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) conference in Barcelona, Spain (October 1-5, 2016). Terumo has exclusive distribution rights of the CytoSorb cardiopulmonary bypass (CPB) procedure pack for cardiac surgery in France, Sweden, Denmark, Norway, Finland, and Iceland.
Throughout the week, the CytoSorb CPB pack will be displayed at both the CytoSorbents and Terumo exhibition booths. Clinicians will be able to talk with trained product specialists to learn more about how and why CytoSorb is used in heart-lung machines during open heart surgery. In addition, potential customers from Terumo’s distribution territory have been invited to daily CytoSorb presentations to hear more about CytoSorb technology as part of Terumo’s clinical education for cardiac surgeons and perfusionists. Directly following EACTS, Terumo will also host a two-day scientific program in Nice, France, bringing together an estimated 40 cardiac surgery perfusionists from throughout France to discuss innovative perfusion strategies where CytoSorb will be a key discussion topic.
“Attracting thousands of participants from across the world, EACTS is one of the largest and most influential international cardiothoracic surgery conferences. We are pleased that Terumo will initiate its CytoSorb CPB marketing efforts at such a high profile event and are confident that these efforts will provide a solid foundation for introducing CytoSorb to Terumo’s cardiac surgery customer base in Europe,” stated Dr. Phillip Chan, CEO of CytoSorbents.
Following these international marketing events, Terumo and CytoSorbents will continue to work closely to move rapidly towards a market launch in Terumo’s distribution territories, expected to begin later this year.
About CytoSorbents Corporation
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is CE Mark certified and is currently distributed in 39 countries around the world as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study evaluating the safety of intra-operative CytoSorb use with a heart-lung machine during complex cardiac surgery. In early 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval. CytoSorb has been used safely in more than 14,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb and others. Additional information is available for download on the Company’s websites: http://www.cytosorbents.com and http://www.cytosorb.com.
About Terumo Cardiovascular Group
Terumo Cardiovascular Group manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring, and vascular grafting. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe and Asia. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties. For more information, visit www.terumo-cvgroup.com.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations, and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events, and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
(732) 329-8885 ext. *825
Public Relations Contact:
SOURCE CytoSorbents Corporation